Warts (HPV)

About Warts (HPV) Clinical Trials (Click to Open)

Join Clinical Trials for Warts (HPV)

Warts (Common and Plantar)

General Purpose 

Although warts can occur anywhere on the body, this information will address only those warts that occur on the hands and feet. A separate section on genital warts is provided here.

At some point in their life, most people will experience the unpleasant occurrence of warts on their hands, fingers, and/or feet. Warts that occur on the hands and fingers are generally rough, flesh-colored, white, pink, or tan in appearance, and often have small black dots (clotted blood vessels) noticeable within their core.

These warts are known as common warts, and are transmitted by touch. Children, young adults, and individuals with compromised immune systems are more likely to develop common warts.

Although these warts tend to disappear on their own, many people resort to over-the-counter medications or minor dermatologic procedures to remove them, due to their often unsightly appearance and resulting embarrassment.

Warts that occur on the soles of the feet are known as plantar warts. They tend to develop on the pressure points of the feet, and can sometimes grow inward beneath a hard, thickened patch of skin. Like common warts, plantar warts usually do not require treatment, but many people prefer to remove them, as they can be bothersome or painful.

In such cases, a dermatologist should be consulted. Treatments may include freezing, mild acid, immunotherapy, minor surgical procedures, and laser therapy. Unfortunately, plantar warts can be resistant to treatment and often require multiple treatments before they disappear.

Both plantar and common warts are caused by the human papillomavirus (HPV), of which there are over 100 different types. Moreover, different strains of the virus cause different types of warts. The HPV strains that cause common warts are contagious, whereas those that cause plantar warts are much less so.

Transmission of common warts occurs via touch, whereas the viruses that cause plantar warts thrive in warm, moist places such as showers, locker rooms, and public swimming facilities. In order to become infected, the virus requires a point of entry into the skin, therefore, cracks in dry skin, cuts, scrapes, and softened skin due to water exposure all provided opportunities for infection with HPV.

What Will Wart-Related Clinical Trials Be Like?

The types of procedures used in wart-related clinical trials will ultimately depend on the specific nature of the study and what types of warts are being studied. Provided below is a list of common procedures, tests, and assessments that may be incorporated into such clinical trials:

  • Detailed physical examination
  • Wart removal / wart biopsy
  • You may be required to take an oral medication, use a topical gel or lotion applied to your warts, or undergo a surgical or skin therapy procedure.
  • Blood tests
  • Photographs of your warts

Typical Wart-Related Clinical Trial Protocol:

Specific examples of clinical trials for warts might include the following:

  • A randomized trial comparing the effectiveness of an adhesive patch consisting of moleskin plus duct tape with an adhesive patch consisting of moleskin alone for treating plantar warts. The purpose of such a trial would be to determine if duct tape, which is anecdotally reported to be effective at treating both plantar and common warts, is effective in a controlled setting for the treatment of plantar warts.
  • A study to determine which of four different strengths of a newly developed anti-fungal gel is effective at treating common warts when administered three times per week for twelve weeks.
  • A randomized clinical trial in which patients with common and/or plantar warts receive either a newly developed oral antifungal medication or a placebo. The purpose of this trial would be to determine if the new medication is safe and effective as a treatment for common and plantar warts.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” treatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

On occasion, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo. Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug or therapy is being investigated (such as the third clinical trial example described above), the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

It is important to know that placebo-only trials are only conducted when scientifically necessary and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular disease or condition.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors. Therefore, it is important to know as many details as possible with regard to your specific circumstances when searching for clinical trials.  Examples of information you may want to have on hand include the following:

  • Your history of warts
  • Your prior and current diagnoses of any other health conditions or diseases
  • Your current medications (including vitamins, minerals, and other dietary supplements)

Suggested Search Terms:

Once you are ready to begin your search for wart-related clinical trials, the following terms may be of use when combined with either “common warts” or “plantar warts”: “treatment,” “prevention,” “children,” and “adolescents.”


 

Current Search Term:

“Warts (HPV)”

Add Comments or Questions



Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers


Condition:   Human Papillomavirus
Interventions:   Drug: GX-I7;   Drug: Placebo
Sponsor:   Genexine, Inc.
Recruiting - verified April 2017


Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics


Condition:   Human Papillomavirus (HPV)
Interventions:   Behavioral: Provider assessment and feedback;   Behavioral: Provider reminders;   Behavioral: Provider education;   Behavioral: Patient reminders;   Behavioral: Parent education
Sponsors:   The University of Texas Health Science Center, Houston;   Cancer Prevention Research Institute of Texas;   Baylor College of Medicine
Recruiting - verified April 2017


A Phase I Study of Quadrivalent HPV Recombinant Vaccine


Condition:   HPV Infections
Interventions:   Biological: HPV vaccine;   Biological: Placebo
Sponsor:   Shanghai Bovax Biotechnology Co., Ltd.
Active, not recruiting - verified March 2017


HPV Infections, Cancer of the Vulva and Therapeutical Success


Conditions:   HPV;   Human Papilloma Virus
Intervention:   Diagnostic Test: polymerase chain reaction
Sponsors:   University of Luebeck;   EUROIMMUN Medizinische Labordiagnostika AG
Recruiting - verified March 2017


HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation


Condition:   HPV Infection
Intervention:   Biological: GARDASIL 9
Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.;   University Cancer Foundation;   Duncan Family Institute for Cancer Prevention and Risk Assessment
Recruiting - verified April 2017


Txt2Protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men


Condition:   Human Papillomavirus
Interventions:   Behavioral: Txt2Protect;   Behavioral: Sexual Health Knowledge Control
Sponsors:   Northwestern University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Not yet recruiting - verified December 2016


Evaluation of the Implementation and Effectiveness of IPP-HPV


Condition:   HPV Vaccination
Interventions:   Drug: HPV vaccine;   Behavioral: Inpatient Postpartum HPV Immunization Quality Improvement Program
Sponsor:   Yale University
Not yet recruiting - verified December 2016


Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake


Conditions:   Human Papillomavirus Virus;   HPV
Interventions:   Behavioral: Web App Intervention Group;   Behavioral: Usual Customary Care Group
Sponsors:   Klein Buendel, Inc.;   University of New Mexico;   Indiana University
Active, not recruiting - verified December 2016


Quarterback 2 - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer


Condition:   Locally Advanced HPV Positive Oropharynx Cancer
Interventions:   Radiation: PTV56;   Radiation: PTV50.4
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting - verified October 2016


Human Papillomavirus Anal Infection


Condition:   HPV Infection
Intervention:   Procedure: HPV detection in anal canal samples
Sponsor:   Centre Hospitalier Universitaire de Besancon
Completed - verified August 2016


Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer


Condition:   HPV Infection
Intervention:   Biological: Human papillomavirus genotyping
Sponsor:   CHU de Reims
Completed - verified June 2016


Observational Follow up of Prior HPV Vaccinees


Condition:   Human Papillomavirus Virus
Intervention:   Other: venepuncture
Sponsor:   Public Health England
Recruiting - verified April 2017


Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections


Condition:   Cervical HPV-16 and / or HPV-18 Infection
Interventions:   Drug: Yallaferon®, the recombinant human interferon α-2b gel;   Other: gel without active ingredient
Sponsor:   Lee's Pharmaceutical Limited
Recruiting - verified June 2016


Educational Intervention to Improve HPV Vaccination Decision Quality


Condition:   HPV Vaccination Decision Quality
Interventions:   Behavioral: Tailored educational materials;   Behavioral: Untailored educational materials;   Behavioral: Survey only
Sponsors:   University of Colorado, Denver;   University of Michigan
Completed - verified July 2016


Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children


Condition:   HPV Vaccination
Interventions:   Behavioral: Assessments;   Other: Text Message Reminder;   Other: No Text Messaging
Sponsors:   Memorial Sloan Kettering Cancer Center;   The City College of New York
Recruiting - verified March 2017


Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens


Condition:   Human Papilloma Virus Infection
Interventions:   Other: Thinprep® LBC;   Other: APTIMA® HPV Assay;   Other: HR HC2® HPV DNA;   Other: Colposcopy
Sponsors:   Hologic Deutschland GmbH;   University Hospital Tuebingen
Active, not recruiting - verified February 2017


Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL


Condition:   HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL
Interventions:   Drug: GTL001+;   Drug: Aldara
Sponsors:   Genticel;   PPD
Terminated - verified October 2016


Strengthening Physician Communication About HPV Vaccines


Condition:   HPV Immunization Status
Intervention:   Behavioral: Multimodal Vaccine Program
Sponsors:   University of Colorado, Denver;   Centers for Disease Control and Prevention
Active, not recruiting - verified January 2017


Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies


Conditions:   Human Papillomavirus (HPV)-Related Malignancies;   Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Intervention:   Drug: Ribavirin
Sponsor:   Memorial Sloan Kettering Cancer Center
Active, not recruiting - verified May 2017


HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer


Condition:   Subjects With p16+/HPV+ Squamous Cell Carcinomas of the Oropharynx.
Intervention:   Other: Obtaining Human tissue
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified September 2016


Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma


Condition:   HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions:   Drug: Cetuximab;   Radiation: RT (70 Gy in 35 fractions);   Drug: Cisplatin
Sponsor:   Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2017


A Phase I Clinical Trial of an HPV Therapeutic Vaccine


Condition:   Human Papillomavirus
Intervention:   Biological: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
Sponsors:   University of Arkansas;   National Cancer Institute (NCI)
Completed - verified October 2016


HPV Vaccine Effectiveness in Partially Vaccinated Girls in Uganda


Conditions:   HPV16 Anitbody Levels Post Vaccination;   HPV18 Antibody Levels Post Vaccination
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 18, 2016


Prevention of HPV in 20 to 45 Year Old Chinese Women (V501-041)


Condition:   HPV Infections
Interventions:   Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine;   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017


Pilots of Self-Collection for HPV DNA Detection


Condition:   HPV
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed - verified December 13, 2011

Refine Your Search Advanced Search